These results underscore the robust immunomodulatory and anti‐tumor capabilities of the cmExoaCD11b platform in both murine and PDX pancreatic cancer model, providing valuable insights for the clinical exploration of STING pathway‐based immunotherapies. This evidence concerns the gene STING1 and pancreatic neoplasm.